NCT Number: NCT00184756
Efficacy on Height in SGA Children Treated With Growth Hormone
This trial is conducted in Europe and Middle East. Growth hormone in SGA Children This trial compares a treated group of patients with an untreated group of patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
3 year–7 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Novo Nordisk Investigational Site, Brno, Czechia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Born small for gestational age with length and/or weight at -2 SDS or below at time of birth, according to country specific references.
- Severe growth failure with no catch up and with height at -2.5 SDS or below, according to country specific references, for chronological age at time of inclusion
Exclusion criteria
- Growth Hormone Deficiency (GHD)
- Treatment with any medical product which may interfere with GH effects
- Growth retardation associated with infections, severe chronic diseases including chromosomal anomaly or nutritional disorders
Treatment and study plan
Primary outcomes
-
Evaluate effect on Height in SGA Children Treated with Growth Hormone
Time frame: After 2 years of treatment
Secondary outcomes
-
Appetite
-
Height SDS, yearly
Sponsors and collaborators
Lead sponsor
Novo Nordisk A/S
Industry
Registry information
Official study title
Effect of Two Years Treatment With Growth Hormone on Height in SGA Children.
Important dates
- Study start
- 2002
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Sep 16, 2005
- Registry last updated
- Jan 13, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
NCT01110928
Foetal Growth Problem, Small for Gestational Age
Tokyo, Japan
View Trial DetailsObservational Prospective Study on Patients Treated With Norditropin®
NCT00960128
Adult Growth Hormone Deficiency, Bone Diseases
Prov. de Buenos Aires, Argentina
View Trial DetailsGrowth Hormone Treatment in Children Born Small for Gestational Age (SGA)
NCT00184717
Foetal Growth Problem, Small for Gestational Age
Tokyo, Japan
View Trial DetailsLong Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
NCT01734447
Foetal Growth Problem, Small for Gestational Age
Paris, France
View Trial Details